Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748149 | 0.84 | NPC1 (0.63) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL1008997 | 0.84 | NPC1 (0.58) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL1011248 | 0.84 | PABPC1 (0.59) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL28395190 | 0.81 | MAPT (0.54) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL25389520 | 0.81 | ALDH1A1 (0.66) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL9702763 | 0.81 | NPC1 (0.59) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL28242830 | 0.81 | NPC1 (0.67) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL1703340 | 0.80 | ABCB1 (0.52) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL2791886 | 0.80 | ABCB1 (0.61) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL31084267 | 0.79 | NPC1 (0.67) | NPC1POLBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231680-B1 | LIGANDS FOR TRANSITION-METAL-CATALYZED CROSS-COUPLINGS, AND METHODS OF USE THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2018-03-28 | — | — | EP | disclosed |
| US-8981086-B2 | Phosphine-ligated palladium sulfonate palladacycles | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150045570-A1 | PHOSPHINE-LIGATED PALLADIUM SULFONATE PALLADACYCLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| US-8889857-B2 | Phosphine-ligated palladium sulfonate palladacycles | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-11-18 | — | — | US | disclosed |
| EP-1339706-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045570-A1 | PHOSPHINE-LIGATED PALLADIUM SULFONATE PALLADACYCLES | PHOSPHO1, PDCD1, PDCD1LG2 | NPC1 4689/4885POLB 1259/4885MAPT 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.